ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC 50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research In Vitro ONO-0300302 shows moderate stability against rat microsomes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ONO-0300302 inhibits significantly an LPA (lysophosphatidic acid receptor)-induced increase of intraurethral pressure (IUP) in rat (3 mg/kg, p.o.) and dog (1 mg/kg, p.o.) over 12 h . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:LPA1 Receptor 0.086 μM (IC 50 )